Rizatriptan is a selective serotonin receptor agonist primarily used in the treatment of acute migraine attacks. It belongs to the triptan class of medications, which are designed to alleviate migraine symptoms by targeting serotonin receptors in the brain. The chemical structure of rizatriptan features a 5-HT_1B and 5-HT_1D receptor agonism, which helps to constrict dilated cranial blood vessels and inhibit the release of pro-inflammatory neuropeptides. Rizatriptan is typically administered orally and is known for its rapid onset of action, making it effective in providing relief from migraine symptoms. The substance is characterized by its relatively high solubility in water and moderate lipophilicity, which influences its pharmacokinetic properties. Common side effects may include dizziness, fatigue, and nausea, while contraindications include cardiovascular conditions due to its vasoconstrictive properties. Overall, rizatriptan is a well-established option for migraine management, offering patients a targeted approach to alleviating acute migraine episodes.

Rizatriptan

174610-17-4: Rizatriptan is a selective serotonin receptor agonist primarily used in the treatment of acute migraine attacks. It belongs to the triptan class of medications, which are designed to alleviate migraine symptoms by targeting serotonin receptors in the brain. The chemical structure of rizatriptan features a 5-HT_1B and 5-HT_1D receptor agonism, which helps to constrict dilated cranial blood vessels and inhibit the release of pro-inflammatory neuropeptides. Rizatriptan is typically administered orally and is known for its rapid onset of action, making it effective in providing relief from migraine symptoms. The substance is characterized by its relatively high solubility in water and moderate lipophilicity, which influences its pharmacokinetic properties. Common side effects may include dizziness, fatigue, and nausea, while contraindications include cardiovascular conditions due to its vasoconstrictive properties. Overall, rizatriptan is a well-established option for migraine management, offering patients a targeted approach to alleviating acute migraine episodes.

CAS 174610-17-4

Rizatriptan

Rizatriptan Impurity 7

Ref: ST-EA-CP-R18024